[
  {
    "ts": null,
    "headline": "Qiagen (QGEN) Down 6% Since Last Earnings Report: Can It Rebound?",
    "summary": "Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "url": "https://finnhub.io/api/news?id=c476aade2932654a33c27695e4be94241e12fc7fccb1a6936e4fe75a02939bc3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741365062,
      "headline": "Qiagen (QGEN) Down 6% Since Last Earnings Report: Can It Rebound?",
      "id": 133185019,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "url": "https://finnhub.io/api/news?id=c476aade2932654a33c27695e4be94241e12fc7fccb1a6936e4fe75a02939bc3"
    }
  },
  {
    "ts": null,
    "headline": "Dow's nearly 150-point rally led by gains in IBM, Verizon stocks",
    "summary": "Dow's nearly 150-point rally led by gains in IBM, Verizon stocks",
    "url": "https://finnhub.io/api/news?id=9d8713d3a0ffcd0a062f0d98ece59bf2bb2f4cf651d9890109a72c5bf342d5a2",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741362180,
      "headline": "Dow's nearly 150-point rally led by gains in IBM, Verizon stocks",
      "id": 133104926,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Dow's nearly 150-point rally led by gains in IBM, Verizon stocks",
      "url": "https://finnhub.io/api/news?id=9d8713d3a0ffcd0a062f0d98ece59bf2bb2f4cf651d9890109a72c5bf342d5a2"
    }
  },
  {
    "ts": null,
    "headline": "IBM, Verizon share gains lead Dow's 250-point jump",
    "summary": "IBM, Verizon share gains lead Dow's 250-point jump",
    "url": "https://finnhub.io/api/news?id=9d397a9f8dd02ce2fcd406ef21d6f116a2e8b3c1c1c4228aaeb8f1fe9362f7e4",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741358340,
      "headline": "IBM, Verizon share gains lead Dow's 250-point jump",
      "id": 133104927,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "IBM, Verizon share gains lead Dow's 250-point jump",
      "url": "https://finnhub.io/api/news?id=9d397a9f8dd02ce2fcd406ef21d6f116a2e8b3c1c1c4228aaeb8f1fe9362f7e4"
    }
  },
  {
    "ts": null,
    "headline": "Dow's 114-point rally highlighted by gains in IBM, Verizon shares",
    "summary": "Dow's 114-point rally highlighted by gains in IBM, Verizon shares",
    "url": "https://finnhub.io/api/news?id=157d95000339e52076b0a32a2d09b6585f542f1c7fb8be751bda170684a6bb5a",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741354680,
      "headline": "Dow's 114-point rally highlighted by gains in IBM, Verizon shares",
      "id": 133104692,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Dow's 114-point rally highlighted by gains in IBM, Verizon shares",
      "url": "https://finnhub.io/api/news?id=157d95000339e52076b0a32a2d09b6585f542f1c7fb8be751bda170684a6bb5a"
    }
  },
  {
    "ts": null,
    "headline": "Recession Risk And Pockets Of Strength",
    "summary": "Budweiser keeps pushing higher. AI segments moving down. Bitcoin in short and long-term. Economy not looking as sweet.",
    "url": "https://finnhub.io/api/news?id=68f875920374e19e623e7f3d76e7b8a2c5d5fa48c455f322084e0817d8cfe62b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741348800,
      "headline": "Recession Risk And Pockets Of Strength",
      "id": 133092602,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1201610071/image_1201610071.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Budweiser keeps pushing higher. AI segments moving down. Bitcoin in short and long-term. Economy not looking as sweet.",
      "url": "https://finnhub.io/api/news?id=68f875920374e19e623e7f3d76e7b8a2c5d5fa48c455f322084e0817d8cfe62b"
    }
  },
  {
    "ts": null,
    "headline": "2 Dividend Stocks to Buy for a Lifetime of Passive Income",
    "summary": "Dividend investors don't buy shares of companies hoping they will suspend their payouts soon.  The longer a corporation maintains its dividend program, the more attractive it is to income seekers, all else being equal.  Let's discuss two that have what it takes to pay investors regular dividends for good: Amgen (NASDAQ: AMGN) and AbbVie (NYSE: ABBV).",
    "url": "https://finnhub.io/api/news?id=68e6f0a6f97e943f5b93938ce6707ef21444de09ae23e8101973d69abd49fa67",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741341780,
      "headline": "2 Dividend Stocks to Buy for a Lifetime of Passive Income",
      "id": 133185020,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Dividend investors don't buy shares of companies hoping they will suspend their payouts soon.  The longer a corporation maintains its dividend program, the more attractive it is to income seekers, all else being equal.  Let's discuss two that have what it takes to pay investors regular dividends for good: Amgen (NASDAQ: AMGN) and AbbVie (NYSE: ABBV).",
      "url": "https://finnhub.io/api/news?id=68e6f0a6f97e943f5b93938ce6707ef21444de09ae23e8101973d69abd49fa67"
    }
  },
  {
    "ts": null,
    "headline": "Wegovy's price cut, Amgen's Ozempic competitor, and Big Pharma's tax cut: Pharma news roundup",
    "summary": "Novo Nordisk just cut the price of its weight-loss drug, Wegovy, by more than half for patients who pay without insurance. Amgen (AMGN) announced this week that it has begun two late-stage clinical trials for its experimental weight-loss drug, MariTide. And Big Pharma is lobbying for a tax break that would have saved it at least $15 billion in 2023.",
    "url": "https://finnhub.io/api/news?id=9a2bbef40445bd567ecef788723d52383eef021996c7d869bbb90c819cd5c76f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741341600,
      "headline": "Wegovy's price cut, Amgen's Ozempic competitor, and Big Pharma's tax cut: Pharma news roundup",
      "id": 133185021,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Novo Nordisk just cut the price of its weight-loss drug, Wegovy, by more than half for patients who pay without insurance. Amgen (AMGN) announced this week that it has begun two late-stage clinical trials for its experimental weight-loss drug, MariTide. And Big Pharma is lobbying for a tax break that would have saved it at least $15 billion in 2023.",
      "url": "https://finnhub.io/api/news?id=9a2bbef40445bd567ecef788723d52383eef021996c7d869bbb90c819cd5c76f"
    }
  }
]